{"id":42996,"date":"2025-10-10T15:42:11","date_gmt":"2025-10-10T07:42:11","guid":{"rendered":"https:\/\/flcube.com\/?p=42996"},"modified":"2025-10-10T15:42:12","modified_gmt":"2025-10-10T07:42:12","slug":"takeda-shuts-down-cell%e2%80%91therapy-program-eyes-external-collaboration-for-%ce%b3%ce%b4-t%e2%80%91cell-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=42996","title":{"rendered":"Takeda Shuts Down Cell\u2011Therapy Program, Eyes External Collaboration for \u03b3\u03b4 T\u2011Cell Platform"},"content":{"rendered":"\n

Takeda Pharmaceutical Co., Ltd. (TYO: 4502<\/a>, NYSE: TAK<\/a>) announced today that it is discontinuing all internal cell\u2011therapy development as part of a broader portfolio\u2011prioritization initiative. The decision follows a strategic assessment that the company will seek an external partner to leverage its proprietary \u03b3\u03b4 T\u2011cell platform technologies and accelerate the progress of its clinic\u2011ready programs in this area. Takeda currently has no active clinical trials employing cell\u2011therapy modalities.<\/p>\n\n\n\n

Re\u2011Allocation of Resources Toward Rapid\u2011Delivery Therapeutics<\/strong>
The company will concentrate near\u2011term capital and talent on modalities that can deliver transformative treatments at speed and scale. Preclinical pipelines in small molecules, biologics, and antibody\u2011drug conjugates are advancing a slate of highly innovative candidates poised for clinical translation.<\/p>\n\n\n\n

Background on the Discontinued Platform<\/strong>
Takeda\u2019s cell\u2011therapy efforts were anchored by the \u03b3\u03b4 T\u2011cell platform it acquired in 2021 through the purchase of UK\u2011based GammaDelta Therapeutics. With the program\u2019s termination, Takeda expects an impairment charge of roughly JPY\u202f58\u202fbillion in the second quarter of fiscal year\u202f2025 (ending March\u202f31\u202f2026), primarily relating to intangible assets tied to the \u03b3\u03b4 T\u2011cell technology.<\/p>\n\n\n\n

Financial and Strategic Outlook<\/strong>
While the impairment will impact Q2 FY2025 earnings, Takeda\u2019s leadership believes that the re\u2011prioritization will enhance shareholder value over the long term. The company remains committed to advancing its pipeline of small\u2011molecule and biologic therapies, positioning itself as a key player in oncology and immuno\u2011oncology.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) announced today that it is discontinuing all…<\/p>\n","protected":false},"author":1,"featured_media":42998,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[77,874,1141],"class_list":["post-42996","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-cell-therapy","tag-nyse-tak","tag-tyo-4502"],"yoast_head":"\nTakeda Shuts Down Cell\u2011Therapy Program, Eyes External Collaboration for \u03b3\u03b4 T\u2011Cell Platform - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) announced today that it is discontinuing all internal cell\u2011therapy development as part of a broader portfolio\u2011prioritization initiative. The decision follows a strategic assessment that the company will seek an external partner to leverage its proprietary \u03b3\u03b4 T\u2011cell platform technologies and accelerate the progress of its clinic\u2011ready programs in this area. Takeda currently has no active clinical trials employing cell\u2011therapy modalities.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=42996\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Takeda Shuts Down Cell\u2011Therapy Program, Eyes External Collaboration for \u03b3\u03b4 T\u2011Cell Platform\" \/>\n<meta property=\"og:description\" content=\"Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) announced today that it is discontinuing all internal cell\u2011therapy development as part of a broader portfolio\u2011prioritization initiative. The decision follows a strategic assessment that the company will seek an external partner to leverage its proprietary \u03b3\u03b4 T\u2011cell platform technologies and accelerate the progress of its clinic\u2011ready programs in this area. Takeda currently has no active clinical trials employing cell\u2011therapy modalities.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=42996\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-10T07:42:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-10T07:42:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1001.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42996#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42996\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Takeda Shuts Down Cell\u2011Therapy Program, Eyes External Collaboration for \u03b3\u03b4 T\u2011Cell Platform\",\"datePublished\":\"2025-10-10T07:42:11+00:00\",\"dateModified\":\"2025-10-10T07:42:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42996\"},\"wordCount\":253,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42996#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1001.webp\",\"keywords\":[\"Cell-therapy\",\"NYSE: TAK\",\"TYO: 4502\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42996#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42996\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=42996\",\"name\":\"Takeda Shuts Down Cell\u2011Therapy Program, Eyes External Collaboration for \u03b3\u03b4 T\u2011Cell Platform - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42996#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42996#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1001.webp\",\"datePublished\":\"2025-10-10T07:42:11+00:00\",\"dateModified\":\"2025-10-10T07:42:12+00:00\",\"description\":\"Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) announced today that it is discontinuing all internal cell\u2011therapy development as part of a broader portfolio\u2011prioritization initiative. The decision follows a strategic assessment that the company will seek an external partner to leverage its proprietary \u03b3\u03b4 T\u2011cell platform technologies and accelerate the progress of its clinic\u2011ready programs in this area. Takeda currently has no active clinical trials employing cell\u2011therapy modalities.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42996#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=42996\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42996#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1001.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1001.webp\",\"width\":1080,\"height\":608,\"caption\":\"Takeda Shuts Down Cell\u2011Therapy Program, Eyes External Collaboration for \u03b3\u03b4 T\u2011Cell Platform\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=42996#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Takeda Shuts Down Cell\u2011Therapy Program, Eyes External Collaboration for \u03b3\u03b4 T\u2011Cell Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Takeda Shuts Down Cell\u2011Therapy Program, Eyes External Collaboration for \u03b3\u03b4 T\u2011Cell Platform - Insight, China's Pharmaceutical Industry","description":"Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) announced today that it is discontinuing all internal cell\u2011therapy development as part of a broader portfolio\u2011prioritization initiative. The decision follows a strategic assessment that the company will seek an external partner to leverage its proprietary \u03b3\u03b4 T\u2011cell platform technologies and accelerate the progress of its clinic\u2011ready programs in this area. Takeda currently has no active clinical trials employing cell\u2011therapy modalities.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=42996","og_locale":"en_US","og_type":"article","og_title":"Takeda Shuts Down Cell\u2011Therapy Program, Eyes External Collaboration for \u03b3\u03b4 T\u2011Cell Platform","og_description":"Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) announced today that it is discontinuing all internal cell\u2011therapy development as part of a broader portfolio\u2011prioritization initiative. The decision follows a strategic assessment that the company will seek an external partner to leverage its proprietary \u03b3\u03b4 T\u2011cell platform technologies and accelerate the progress of its clinic\u2011ready programs in this area. Takeda currently has no active clinical trials employing cell\u2011therapy modalities.","og_url":"https:\/\/flcube.com\/?p=42996","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-10T07:42:11+00:00","article_modified_time":"2025-10-10T07:42:12+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1001.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=42996#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=42996"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Takeda Shuts Down Cell\u2011Therapy Program, Eyes External Collaboration for \u03b3\u03b4 T\u2011Cell Platform","datePublished":"2025-10-10T07:42:11+00:00","dateModified":"2025-10-10T07:42:12+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=42996"},"wordCount":253,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=42996#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1001.webp","keywords":["Cell-therapy","NYSE: TAK","TYO: 4502"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=42996#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=42996","url":"https:\/\/flcube.com\/?p=42996","name":"Takeda Shuts Down Cell\u2011Therapy Program, Eyes External Collaboration for \u03b3\u03b4 T\u2011Cell Platform - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=42996#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=42996#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1001.webp","datePublished":"2025-10-10T07:42:11+00:00","dateModified":"2025-10-10T07:42:12+00:00","description":"Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) announced today that it is discontinuing all internal cell\u2011therapy development as part of a broader portfolio\u2011prioritization initiative. The decision follows a strategic assessment that the company will seek an external partner to leverage its proprietary \u03b3\u03b4 T\u2011cell platform technologies and accelerate the progress of its clinic\u2011ready programs in this area. Takeda currently has no active clinical trials employing cell\u2011therapy modalities.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=42996#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=42996"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=42996#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1001.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1001.webp","width":1080,"height":608,"caption":"Takeda Shuts Down Cell\u2011Therapy Program, Eyes External Collaboration for \u03b3\u03b4 T\u2011Cell Platform"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=42996#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Takeda Shuts Down Cell\u2011Therapy Program, Eyes External Collaboration for \u03b3\u03b4 T\u2011Cell Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1001.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=42996"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42996\/revisions"}],"predecessor-version":[{"id":42999,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/42996\/revisions\/42999"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/42998"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=42996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=42996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=42996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}